Latest news with #peptide
Yahoo
7 days ago
- Business
- Yahoo
Atombeat and BioDuro link for peptide drug discovery platform
Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery. The collaboration combines Atombeat's expertise in in silico modelling with BioDuro's capabilities in discovery chemistry, biology, and drug metabolism and pharmacokinetics. The initiative is set to enhance the development of next-generation peptides, quality candidates with quick timelines and cost-effectiveness across various therapeutic areas. Atombeat expedites the discovery of drugs using its Hermite software and RiDYMO platform, incorporating technologies such as Uni-Dock and Reinforced Dynamics. These tools enable the exploration of a digital library with over one trillion potential peptide compounds, streamlining the early drug discovery process. By focusing on the most promising candidates, the platform is designed to save cost, time and effort in drug development. BioDuro's role in the partnership is to leverage its synthesis capability for producing several peptide compounds in parallel. The company will be able to deliver pure peptides within one week, without the need for purification steps. This integrated approach aims to significantly reduce research and development timelines and associated costs and risks. BioDuro CEO Dr Armin Spura stated: 'We are excited to advance peptide innovation through our strategic partnership with Atombeat. Atombeat brings extensive experience in AI-assisted drug design and optimisation. 'Together, we aim to provide the industry with leading services in peptide drug development, accelerating smarter and more efficient peptide research, and delivering faster and comprehensive solutions to our global clients.' The AI-accelerated platform will facilitate a seamless workflow from molecular design to preclinical candidate selection. It is expected to deliver cyclic peptides that meet key developability traits, such as membrane permeability, across a broad range of therapeutic areas. "Atombeat and BioDuro link for peptide drug discovery platform" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Daily Mail
31-07-2025
- Health
- Daily Mail
Two women put on ventilators after taking peptide shots at 'how to live forever' conference
Two women have been put on ventilators after receiving peptide shots at a medical convention focused on how to cheat death. The women, a 38-year-old from California and a 51-year-old from Nevada, who have not been named, were raced to hospital after taking the experimental injections at a booth at the conference in Las Vegas. Organizers of the Revolution Against Aging and Death Festival, otherwise known as RAADfest, say they are investigating the hospitalizations. The doctor who ran the booth where the women took the shots, Dr. Kent Holtorf, promotes himself as a specialist in 'age reversal', but did not have permission to practice medicine in Nevada, according to the Las Vegas Review Journal. Holtorf told ProPublica that he rejects allegations that the peptide injections he gave the women caused them to suddenly fall ill, with the attendees reportedly suffering swelling tongues, accelerated heart rates and breathing problems. 'Of course, I want to get to the bottom of it. But almost assuredly it will come out that it was not the peptides,' he told the outlet. The episode comes as peptides have come under scrutiny following the political rise of Health and Human Services Secretary Robert F Kennedy Jr, an avowed supporter of the therapy as a solution to chronic disease. Holtorf said that he became convinced that the hospitalizations were not caused by peptides after plugging information about the incident into an AI app. He reportedly said that the AI gave him a 57-page report that 'basically says that it is impossible it was the peptides', but he added: 'I don't want to try and push the blame and say it wasn't us... We are reassessing everything we are doing.' While admitting he is not licensed to practice medicine in Nevada, Holtorf said that he hired a practitioner to write prescriptions and administer therapies for him at the booth where the women were injected. 'I knew what was going on but was not hands on,' he said. The RAADfest summit where the incident unfolded is focused on avoiding death and limiting aging, a concept popularized by figures such as Kennedy and 'biohacker' Brian Johnson. Images on social media from the event this year show speakers on stage and at booths with a grim reaper, including at one booth lauding the 'death of death.' According to a police report from the Review Journal, Holtorf ran a booth at the conference offering peptide shots despite only being licensed to practice medicine in California, and not Nevada. The Las Vegas Metropolitan Police reportedly said that as many as seven people fell ill at the event, prompting investigations from the Southern Nevada Health District and the Nevada Board of Pharmacy. The two women who were taken ill were reportedly rushed by ambulance to the hospital, with one intubated by the time she reached the hospital. The other woman suffered side effects including loss of muscle control in her neck, inability to open her eyes and losing the ability to communicate with doctors, the police report said. Peptides are often used in modern medicine for a variety of health conditions, but combining them together can increase risks and are often not approved by medical bodies. The report noted that the women received different peptide combinations, both including at least one compound that poses significant risks when combined with others, according to the FDA. Holtorf insisted that he was 'freaked out' by the reactions because the symptoms didn't make 'any sense', and said he had not seen such reactions in 30 years. He added that it is hard to keep up with which peptide combinations are accepted and which are banned, saying there is 'so much gray area... people know they just get patients better.' James Strole, the organizer of RAADfest, told ProPublica that the two women spent several days in the hospital and are now recovering. He maintained that it is 'not clear the people got sick as a result of treatment from Dr. Holtorf', but was 'anxious' for the incident to be 'deeply investigated.' He added that RAADfest has not had anything similar occur in 10 years of running the conference, but this is the first year that Holtorf offered therapies. Despite the hospitalizations at his event, Strole insisted that peptides are considered 'generally safe' and he takes them himself regularly, but for everyone at his events, 'the big concern is safety.' 'We look at who is doing the administering, whether it's an injection or supplement. We look at the person and the company itself, what the efficacy is, how they operate, their safety measures. We look at all that,' he said.
Yahoo
18-07-2025
- Business
- Yahoo
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S ('Zealand') (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 17 July 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,135,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 10.001% of the total share capital and 10.001% of the total voting rights in Zealand Pharma A/S. Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V., which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543). Ultimately, Van Herk Private Equity Investments B.V. is owned and controlled by Mr. Adrianus van Herk. Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,135,191 shares (each share carrying one vote), corresponding to 10.001% of the total share capital and 10.001% of the total voting rights in Zealand Pharma A/S. Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk. Please see further details in the attached notification forms. # # # About Zealand Pharma Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit ContactAdam Lange (Investors) Vice President, Investor Relations alange@ Neshat Ahmadi (Investors) Investor Relations Manager neahmadi@ Anna Krassowska (Investors and Media) Vice President, Investor Relations & Corporate Communications akrassowska@ Attachments 20250717 FSA - Standardformular english Van Herk Investments BV_final 20250717 FSA - Standardformular english Van Herk Management Services BV_finalSign in to access your portfolio
Associated Press
18-07-2025
- Business
- Associated Press
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S ('Zealand') (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 17 July 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,135,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 10.001% of the total share capital and 10.001% of the total voting rights in Zealand Pharma A/S. Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V., which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543). Ultimately, Van Herk Private Equity Investments B.V. is owned and controlled by Mr. Adrianus van Herk. Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,135,191 shares (each share carrying one vote), corresponding to 10.001% of the total share capital and 10.001% of the total voting rights in Zealand Pharma A/S. Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk. Please see further details in the attached notification forms. # # # About Zealand Pharma Zealand Pharma A/S (Nasdaq: ZEAL) ('Zealand') is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit Contact Adam Lange (Investors) Vice President, Investor Relations [email protected] Neshat Ahmadi (Investors) Investor Relations Manager [email protected] Anna Krassowska (Investors and Media) Vice President, Investor Relations & Corporate Communications [email protected] Attachments
Yahoo
17-07-2025
- Business
- Yahoo
Lisata Secures New Composition of Matter Patent for Certepetide
By Daniella Parra Lisata Therapeutics said it has been granted a new composition of matter patent for its lead drug candidate, certepetide, offering the highest level of IP protection by covering the drug's unique chemical structure, how it's made, and how it's used to treat solid tumor cancers, they said. Certepetide is an investigational peptide drug developed to improve the delivery of anti-cancer therapies into solid tumors, the company said. 'This new patent marks a key milestone, significantly boosting the value of both certepetide and the Company by delaying generic encroachment for essentially the next two decades,' stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata. '[It] greatly strengthens our negotiating position with potential partners, increasing the potential for sustained growth and value creation for our shareholders.' READ MORE HEALTHCAREEDGE Lisata Therapeutics Reports Trial Results for Pancreatic Cancer Treatment Register for our weekly newsletter Contact: Exec Edge Editor@ Click to follow us on LinkedIn
